Hester Biosciences Posts Strong Q2 & H1 FY27 Operational Performance
Hester Biosciences Ltd 路 Transcript 路 07 Nov 2026, 8:31 pm
Hester Biosciences Posts Strong Q2 & H1 FY27 Operational Performance Hester Biosciences reported strong Q2 FY27 standalone revenue growth of 28% YoY, with PAT surging 131% YoY. Standalone gross margin reached 78% and EBITDA margin stood at 35%, driven by favorable product mix and operational discipline despite newly capitalized BSL-3 depreciation. Consolidated Q2 revenue rose 38% YoY, while PAT increased 44% YoY. Poultry Healthcare expanded 27% YoY in Q2 (37% in H1), aided by H9N2 vaccine traction and institutional sales. Capacity utilization stood near 65%, with net debt reduced to approximately INR80 crore.
Original exchange filing (PDF)
More announcements from Hester Biosciences Ltd
- Audio recording of the Earnings Conference Call for Q2 FY 27 路 05 Nov 2026
- Hester Biosciences Limited has informed the Exchange about Board have approved an Unsecured loan of an aggregate amount of USD 1 million to Hester Biosciences Africa Limited( Hester Africa ), foreign wholly-owned subsidiary in Tanzania, in one or more tranches. 路 05 Nov 2026
- Disclosure under regulation 30 of Listing Regulations - Board of Directors approved an unsecured loan to Hester Biosciences Africa Limited, Foreign wholly-owned subsidiary of the Company. 路 05 Nov 2026
- Hester Biosciences Limited has informed the Exchange regarding a press release dated November 05, 2026, titled "20261105 Q2 & H1 FY27 Press Release". 路 05 Nov 2026
- 20261105 Q2 & H1 FY27 Press Release 路 05 Nov 2026
- Hester Biosciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 05 Nov 2026
- Outcome of Board Meeting held on 5 November 2026 and Financial Results for the Q2 & H1 FY 2026-27 路 05 Nov 2026
- This is to inform you that, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company has scheduled investor .... 路 05 Nov 2026
